[1] Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies[J]. Nature, 1997, 388:839-840.
[2] Chojdak-?ukasiewicz J, Dziadkowiak E, Zimny A, Paradowski B. Cerebral small vessel disease:a review[J]. Adv Clin Exp Med, 2021, 30:349-356.
[3] Schwartz RS, Halliday GM, Cordato DJ, Kril JJ. Small-vessel disease in patients with Parkinson's disease:a clinicopathological study[J]. Mov Disord, 2012, 27:1506-1512.
[4] Bergkamp MI, Tuladhar AM, van der Holst HM, van Leijsen EMC, Ghafoorian M, van Uden IWM, van Dijk EJ, Norris DG, Platel B, Esselink RAJ, Leeuw FE. Brain atrophy and strategic lesion location increases risk of parkinsonism in cerebral small vessel disease[J]. Parkinsonism Relat Disord, 2019, 61:94-100.
[5] Wan Y, Hu W, Gan J, Song L, Wu N, Chen Y, Liu Z. Exploring the association between cerebral small-vessel diseases and motor symptoms in Parkinson's disease[J]. Brain Behav, 2019, 9:e01219.
[6] Park YW, Shin NY, Chung SJ, Kim J, Lim SM, Lee PH, Lee SK, Ahn KJ. Magnetic resonance imaging-visible perivascular spaces in basal ganglia predict cognitive decline in Parkinson's disease[J]. Mov Disord, 2019, 34:1672-1679.
[7] Vonsattel JP, Del Amaya MP, Keller CE. Twenty-first century brain banking. Processing brains for research:the Columbia University methods[J]. Acta Neuropathol, 2008, 115:509-532.
[8] Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT; National Institute on Aging, Alzheimer's Association. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease:a practical approach[J]. Acta Neuropathol, 2012, 123:1-11.
[9] Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes[J]. Acta Neuropathol, 1991, 82:239-259.
[10] Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease[J]. Neurobiol Aging, 2003, 24:197-211.
[11] Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology[J]. Clin Geriatr Med, 2020, 36:1-12.
[12] Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Ironside JW, Kavantzas N, King A, Korkolopoulou P, Kovács GG, Meyronet D, Monoranu C, Parchi P, Parkkinen L, Patsouris E, Roggendorf W, Rozemuller A, Stadelmann-Nessler C, Streichenberger N, Thal DR, Kretzschmar H. Staging/typing of Lewy body related alpha-synuclein pathology:a study of the BrainNet Europe Consortium[J]. Acta Neuropathol, 2009, 117:635-652.
[13] Coughlin DG, Petrovitch H, White LR, Noorigian J, Masaki KH, Ross GW, Duda JE. Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but ‘failure to fit’ is highly dependent on staging system applied[J]. Parkinsonism Relat Disord, 2019, 64:124-131.
[14] Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y. Evidence in favor of Braak staging of Parkinson's disease[J]. Mov Disord, 2010, 25 Suppl 1:78-82.
[15] Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease:a clinico-pathological study[J]. Brain, 2010, 133(Pt 6):1755-1762.
[16] van de Berg WD, Hepp DH, Dijkstra AA, Rozemuller JA, Berendse HW, Foncke E. Patterns of α-synuclein pathology in incidental cases and clinical subtypes of Parkinson's disease[J]. Parkinsonism Relat Disord, 2012, 18 Suppl 1:28-30.
[17] Henderson JM, Pell M, O'Sullivan DJ, McCusker EA, Fung VS, Hedges P, Halliday GM. Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease[J]. Mov Disord, 2002, 17:133-137.
[18] Vedam-Mai V, Gardner B, Okun MS, Siebzehnrubl FA, Kam M, Aponso P, Steindler DA, Yachnis AT, Neal D, Oliver BU, Rath SJ, Faull RL, Reynolds BA, Curtis MA. Increased precursor cell proliferation after deep brain stimulation for Parkinson's disease:a human study[J]. PLoS One, 2014, 9:e88770.
[19] Pienaar IS, Lee CH, Elson JL, McGuinness L, Gentleman SM, Kalaria RN, Dexter DT. Deep-brain stimulation associates with improved microvascular integrity in the subthalamic nucleus in Parkinson's disease[J]. Neurobiol Dis, 2015, 74:392-405.
[20] Pal GD, Ouyang B, Serrano G, Shill HA, Goetz C, Stebbins G, Metman LV, Driver-Dunckley E, Mehta SH, Caviness JN, Sabbagh MN, Adler CH, Beach TG; Arizona Study of Aging Neurodegenerative Disorders. Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation[J]. Mov Disord, 2017, 32:274-277.
[21] Vedam-Mai V, Rodgers C, Gureck A, Vincent M, Ippolito G, Elkouzi A, Yachnis AT, Foote KD, Okun MS. Deep brain stimulation associated gliosis:a post-mortem study[J]. Parkinsonism Relat Disord, 2018, 54:51-55.
[22] Holanda VM, Okun MS, Middlebrooks EH, Gungor A, Barry ME, Forder J, Foote KD. Postmortem dissections of common targets for lesion and deep brain stimulation surgeries[J]. Neurosurgery, 2020, 86:860-872.
[23] Haberler C, Alesch F, Mazal PR, Pilz P, Jellinger K, Pinter MM, Hainfellner JA, Budka H. No tissue damage by chronic deep brain stimulation in Parkinson's disease[J]. Ann Neurol, 2000, 48:372-376.
[24] Vedam-Mai V, Baradaran-Shoraka M, Reynolds BA, Okun MS. Tissue response to deep brain stimulation and microlesion:a comparative study[J]. Neuromodulation, 2016, 19:451-458.
[25] Klioueva NM, Rademaker MC, Dexter DT, Al-Sarraj S, Seilhean D, Streichenberger N, Schmitz P, Bell JE, Ironside JW, Arzberger T, Huitinga I. BrainNet Europe's Code of Conduct for brain banking[J]. J Neural Transm (Vienna), 2015, 122:937-940.
[26] Kretzschmar H. Brain banking:opportunities, challenges and meaning for the future[J]. Nat Rev Neurosci, 2009, 10:70-78. |